Aptorum Group Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG6096M1226
USD
1.40
0.1 (7.69%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Aptorum Group Ltd. stock-summary
stock-summary
Aptorum Group Ltd.
Pharmaceuticals & Biotechnology
Aptorum Group Limited is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases, particularly infectious diseases and cancers (including orphan oncology indications). Through the establishment of drug discovery platforms, it enables the discovery of new therapeutics assets through systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. In addition to this, the Company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women’s health and other disease areas. It also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms.
Company Coordinates stock-summary
Company Details
17 Hanover Square , LONDON None : W1S 1BN
stock-summary
Tel: 44 20 80929299
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (1.39%)

Foreign Institutions

Held by 3 Foreign Institutions (0.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Darren Lui
President, Executive Director
Mr. Ian Huen
Chief Executive Officer, Founder, Executive Director
Dr. Clark Cheng
Chief Medical Officer and Executive Director
Mr. Douglas Arner
Non-Executive Independent Director
Mr. Charles Bathurst
Non-Executive Independent Director
Dr. Mirko Scherer
Non-Executive Independent Director
Dr. Justin Wu
Non-Executive Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

-14.26%

stock-summary
Price to Book

0.58